JSE-listed pharmaceutical manufacturer Adcock Ingram expects its results for the financial year to June 30 to show an improvement of at least 20%, or 79.3c, in earnings a share from the 396.3c reported for the financial year ended June 30, 2021.
The company also expects an improvement of at least 20%, or 80.9c, in headline earnings a share, up from the 404.7c reported for the prior financial year.
"This is owing to an improvement in the trading environment relative to the comparative period, which had been adversely impacted by certain factors caused by the first wave of Covid-19.
“In this regard, the company has experienced improved demand in the current period for its over-the-counter and consumer healthcare products," the company said. 